CDIB Capital Group is a financial services company that focuses on accelerating digital transformation and investing in technological innovation.

CDIB Capital Group

Formerly known as China Development Industrial Bank, CDIB Capital Group is the first private development financial institution in Taiwan and a key member of China Development Financial Holding. CDIB capitalizes on its abundant group resources and multiple investment strategies to create outstanding risk-adjusted returns. CDIB also provides investment advisory services and customized private equity fund investment plans, and works hand in hand with its corporate clients to build a long-term successful future together. Focus on raising and managing private equity funds and actively expands asset management business, CDIB continues to play a pivotal leading role in Taiwan's venture capital and private equity market.

CDIB Capital Group 中華開發資本

#中華開發資本 志工活動延續地方創生主軸，邀請同仁一起前往位於雲林虎尾、品牌歷史超過一甲子的#御鼎興柴燒黑豆醬油 ，進入製醬廠，感受時間的滋味。御鼎興團隊更集結地方回憶與資源，打造一場「#飛雀餐桌行動 」的饗宴，也帶領資本同仁前往「#虎尾釀 」，品嘗在地食材釀造的台灣本土手作純釀酒。
 
御鼎興是開發資本#地方創生 支持團隊之一，開發資本除了提供團隊各項培力行動，也鼓勵同仁前往地方創生現場，親身體驗一場「釀」之旅，以實際行動為地方經濟與產業注入活水。
 
The volunteer activities of #CDIB Capital continue to focus on the main theme of “#RegionalRevitalization”. We invite our colleagues to visit Yu-Ding-Shing (YDS), a black bean wood-fired soy sauce manufacturer in Yunlin, which boasts a history of over six decades. Upon entering the sauce-making area, our colleagues were able to experience the taste of time. Additionally, the YDS team gathered local memories and resources to create a feast known as the “Future Dining Table”. They also led colleagues to “FavorLand” to taste Taiwanese local wine brewed with local ingredients.

YDS is one of the teams that CDIB supports in our regional revitalization efforts. In addition to providing various empowerment initiatives to these teams, we encourage our colleagues to personally embark on a “brewing” journey. Through these direct actions, we can inject vitality into the local economy and industry.

#中華開發資本 2023年志工活動結合 #環保、 #永續、 以及 #地方創生 ，與同仁一起上山下海、深入鄉村，關注台灣社會創新量能，推動地方創生永續發展。
而今年我們也將延續「地方創生」主題，向下扎根，與同仁實際到在地環境，進行深度體驗與對話，一起與開發資本支持的 10 支地方創生團隊、台灣地方創生基金會、環境友善種子團隊，創造「人與經濟/環境」生生不息的正向循環 。

In 2023, #CDIB Capital Group's volunteer activities were a harmonious blend of #environmental protection, #sustainability, and #regional revitalization. Our endeavors took us to the mountains, the sea, and the countryside, where we keenly observed Taiwan's social innovation capacity.
This year, we continue our focus on regional revitalization, deeply rooted in the local environment. We encourage our colleagues to immerse themselves in meaningful environmental experiences. Collaborating with 10 local regional revitalization teams, supported by CDIB, the Taiwan Regional Revitalization Foundation, and Friendly Seed, we aim to create a positive cycle that intertwines people, economy, and environment.

中華開發資本旗下兩檔生醫基金於日前舉辦股東會與年會，並邀請到與中華開發淵源深厚的投資戶 Onward Therapeutics 董事長暨執行長葉常菁博士（智擎生技創辦人與前執行長） ，與 6 月底剛成功將主力產品授權給 Nasdaq 掛牌公司的國邑藥品總經理甘霈博士，分享他們的產品研發歷程，也增加產業與投資人的交流機會。

Two CDIB healthcare funds recently held shareholder meetings and annual meetings to deepen relations with investors. To increase dialogue between the industry and investors, senior executives of two portfolio companies were invited to deliver speeches and share their product development processes. The distinguished guests included Grace Yeh, CEO and Chairperson of Onward Therapeutics SA, as well as the founder and former CEO of PharmaEngine, and Pei Kan, President of Pharmosa Biopharm, who successfully authorized their main pipeline to a Nasdaq-listed company at the end of June.

CDIB Tokyo Innovation Hub 積極扮演台日、產業及政府新創資源對接橋梁，今年陸續於東京與數位產業署副署長胡貝蒂及其同仁討論新創產業發展對策、接待「阿里巴巴創業者基金」拜訪並共同舉辦台日新創交流會、與國發會旗下「Startup Island TAIWAN」及台灣新創媒體「數位時代」合辦三日台日企業交流及創新沙龍小聚。
CDIB Tokyo Innovation Hub 以建構台日投資生態系統為目標，繼續發展跨國合作、深化夥伴關係、協助台灣新創獲取創業資源、進軍國際！

The CDIB Tokyo Innovation Hub serves as a bridge to connect industry and government resources with the startup communities in Taiwan and Japan. Earlier this year, Betty Hu, Deputy Director-General of the Administration for Digital Industries in Taiwan, visited the CDIB Tokyo Innovation Hub to discuss startup development strategies. The CDIB Tokyo Innovation Hub also held the "Japan and Taiwan Innovation Meeting" with Alibaba Entrepreneurs Fund and co-organized a three-day event called "Taiwan Startup Delegation Meetups" with "Startup Island Taiwan", associated with the National Development Council (NDC) in Taiwan and Business Next, a media group with a focus on the startup community.
The CDIB Tokyo Innovation Hub aims to build a Taiwan-Japan investment ecosystem by developing cross-border cooperation, deepening partnerships, and assisting Taiwan's startups with entering the international market.

#CDIB #CDIBTokyoInnovationHub #StartUpIslandTaiwan  #AlibabaEntrepreneursFund #數位時代

中華開發資本祝您新年鴻運昌龍！

For the upcoming Year of the Dragon, CDIB wishes you and your families a Happy Lunar New Year!

#中華開發資本 旗下 #華創毅達生醫基金 投資戶 #賽煒醫療 之核心產品全眼掃頻OCT榮獲享譽國際的權威醫療科技雜誌 Medical Tech Outlook「2023年度全球最佳眼底影像設備品牌」，產品入駐全球頂級、連續20年蟬聯全美第一的眼科中心Bascom Palmer。華創毅達生醫基金看好賽煒近年連續發佈多項具領先優勢的頂尖技術、創新的眼科設備、及具有全球化商業前景，於2023年3月參與賽煒C輪融資。

開發資本團隊於2019年底成立華創毅達生醫基金，致力於發掘大中華區醫療健康投資機會，搭配開發資本超過六十年的投資經驗、人脈網絡資源，已成為生醫創業家的良好戰略夥伴；同時，由開發資本與財團法人工業技術研究院共同推動的「#生醫創新跨域合作平臺 」，也讓生醫產業的研發能量延伸至資本與產業界，將使開發資本逐步打造的台灣及兩岸生醫投資生態系架構及互補機制更形完整。

Intalight Inc., a portfolio company of the #CDIB Yida Healthcare Private Equity Fund, has recently been awarded as the "Top Retinal Imaging Solutions Provider 2023" by Medical Tech Outlook, the world's leading medical magazine. Additionally, it has launched its product in the world's top ophthalmology center, Bascom Palmer (ranked #1 in the USA for 20 consecutive years). CDIB Yida Healthcare Private Equity Fund expressed optimism about Intalight's technical capabilities and the prospects of global business, investing in #Intalight in March 2023. 

CDIB established the CDIB Yida Healthcare Private Equity Fund at the end of 2019, is committed to exploring medical and health investment opportunities in Greater China. With a network of resources and over 60 years of investment experience, CDIB has become a strategic partner for biomedical entrepreneurs. Simultaneously, the "Biomedical Innovation Cross-Domain Cooperation Platform," jointly promoted by CDIB and the Industrial Technology Research Institute, extends the R&D capabilities of the biomedical industry to the capital and industrial sectors. This initiative contributes to the gradual completion of the Taiwan and cross-strait biomedical investment ecosystem and complementary mechanisms built by CDIB.

Metric
Company Name	CDIB Capital Group
Symbol
MSH ID	COM:CDIBCAPITALGROUP
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Management
Country	TW
Stage
Employee Count	98
Website	cdibcapitalgroup.com
LinkedIn	cdib-capital-group
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CDIBCAPITALGROUP

CDIB Capital Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue